GSK.L

GSK plc
$1,915.00
+0.50 (+0.03%)
Mkt Cap 76.42B
Volume 5,933,820
52W Range 1288.605-2282
Sector Healthcare
Beta 0.30
EPS (TTM) 1.45
P/E Ratio 1320.69
Revenue (TTM) 32.78B
Rev Growth (5Y) -0.9%
EPS Growth (5Y) -0.5%

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 32.67B 31.38B 30.33B 29.32B 24.70B 34.10B 33.75B 30.82B 30.19B 27.89B 23.92B 23.01B
Net Income 5.72B 2.58B 4.93B 14.96B 4.38B 5.75B 4.64B 3.62B 1.53B 912.00M 8.42B 2.76B
EPS 1.41 0.63 1.22 3.71 1.37 1.44 1.17 0.92 0.39 0.23 2.18 0.72
Free Cash Flow 5.96B 3.57B 4.42B 5.14B 5.02B 6.20B 5.86B 6.62B 4.72B 4.14B N/A N/A
FCF / Share 1.47 0.88 1.09 1.28 1.57 1.56 1.48 1.69 1.21 1.07 N/A N/A
Operating CF 7.30B 6.55B 6.77B 7.40B 7.95B 8.44B 8.02B 8.42B 6.92B 6.50B N/A N/A
Total Assets 61.12B 59.46B 59.01B 60.15B 79.10B 80.43B 79.69B 58.07B 56.38B 59.08B N/A N/A
Total Debt 17.72B 16.99B 18.02B 20.99B 24.17B 27.15B 30.51B 26.06B 17.09B 18.79B N/A N/A
Cash & Equiv 3.15B 3.69B 2.75B 3.52B 4.07B 6.09B 4.51B 3.87B 3.83B 4.90B N/A N/A
Book Value 16.38B 13.67B 13.35B 10.60B 15.05B 14.59B 11.40B 3.78B (68.00M) 1.12B N/A N/A
Return on Equity 0.35 0.19 0.37 1.41 0.29 0.39 0.41 0.96 N/A 0.81 N/A N/A
GSK.L News
JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited
Apr 30, 2026 06:32 AM · proactiveinvestors.com
Ideal Power to host Q1 2026 earnings conference call on May 14
Apr 30, 2026 01:49 AM · proactiveinvestors.com
OTC Markets Group adds Charlotte’s Web to OTCQX Best Market
Apr 30, 2026 01:36 AM · proactiveinvestors.com
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio
Apr 26, 2026 11:58 PM · proactiveinvestors.com
88 Energy and Burgundy amend Phoenix arrangements
Apr 26, 2026 11:46 PM · proactiveinvestors.com
Bango targets positive cash earnings from subscriptions division in 2027 after strong start to year
Apr 26, 2026 11:23 PM · proactiveinvestors.com
GSK sells rights to rare liver disease drug for up to $690m
Mar 09, 2026 12:12 AM · proactiveinvestors.com
GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments
Feb 24, 2026 09:27 PM · proactiveinvestors.com
Citi lifts GSK target price but keeps neutral stance after rally
Feb 09, 2026 02:03 AM · proactiveinvestors.com
ShoreCap says GSK has cracked it and the £40bn prize is now in sight
Feb 06, 2026 12:10 AM · proactiveinvestors.com